Failure to improve parameters of lactose maldigestion using the multiprobiotic product VSL3 in lactose maldigesters: a pilot study.
Lactose maldigestion is a common genetic trait in up to 70% of the world's population. In these subjects, the ingestion of lactose may lead to prebiotic effects which can be confirmed by measurement of breath hydrogen. After a period of continuous lactose ingestion, colonic bacterial adaptation is measurable as improved parameters of lactose digestion. There may be inherent benefits in this process of adaptation which may protect against some diseases. We attempt to link therapeutically beneficial probiotics (VSL3, Seaford Pharmaceuticals Inc, Ontario) with improvement in parameters of lactose maldigestion. Two groups of five subjects with maldigestion were fed one or four packets of VSL3 (one packet containing 450 x 10(9) live bacteria) before testing and then 17 days later. A 50 g lactose challenge was carried out before and after feeding. While there was a trend toward increasing rather than reducing of summed breath hydrogen, no statistically significant changes were observed between results from before testing and those from testing 17 days later. The authors conclude that direct consumption of the probiotic VSL3 may not improve parameters of lactose maldigestion without metabolic activation. In its present format, therefore, the test for colonic adaptation cannot be used to demonstrate direct bacterial embedding with VSL3.
Department of Medicine, McGill University School of Medicine, Montreal, Quebec.
Rose
R
Yesovitch
Albert
A
Cohen
Andrew
A
Szilagyi
D000222:Adaptation, Physiological; D000328:Adult; D000368:Aged; D001944:Breath Tests; D002170:Canada; D005260:Female; D006801:Humans; D006859:Hydrogen / Q000032:analysis; D007422:Intestines / Q000201:enzymology / Q000382:microbiology; D043322:Lactase; D007785:Lactose; D007787:Lactose Intolerance / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D019936:Probiotics / Q000627:therapeutic use*; D012107:Research Design; D001616:beta-Galactosidase / Q000172:deficiency
D006859:Hydrogen; D043322:Lactase; D001616:beta-Galactosidase; D007785:Lactose